Axsome Therapeutics Inc. (AXSM)
NASDAQ:AXSM
Want to see AXSM full AI Analyst Report?
AXSM Stock Chart & Stats
$188.99
-$0.23(-0.27%)
At close: 4:00 PM EST
$188.99
-$0.23(-0.27%)
Day’s Range― - ―
52-Week Range$96.09 - $238.56
Previous CloseN/A
Volume140.83K
Average Volume (3M)824.86K
Market Cap
$12.02B
Enterprise Value$11.98B
Total Cash (Recent Filing)$305.11M
Total Debt (Recent Filing)$216.71M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Aug 10, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.73
Shares Outstanding51,459,766
10 Day Avg. Volume654,042
30 Day Avg. Volume824,862
Financial Highlights & Ratios
PEG Ratio1.29
Price to Book (P/B)102.90
Price to Sales (P/S)14.23
P/FCF Ratio-96.78
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue16.91
Enterprise Value/Gross Profit18.26
Enterprise Value/Ebitda-69.35
Forecast
1Y Price Target
$265.13Price Target Upside40.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$983.80M
Bulls Say, Bears Say
Bulls Say
High Revenue Growth & Gross MarginsSustained rapid revenue scale to $708M TTM combined with very high gross margins (~91%–93%) indicates attractive product economics. These durable margin characteristics give room for operating leverage as commercialization costs normalize, supporting a path to structural profitability if scale continues.
Regulatory Win Expands Addressable MarketThe FDA approval of AUVELITY for agitation in Alzheimer’s is a first-in-class regulatory milestone that materially expands the drug's label and addressable population. This durable approval supports sustained prescription growth across care settings and strengthens long-term commercial prospects beyond MDD.
Long-term Exclusivity Clarified For SUNOSISettlement resolving SUNOSI patent disputes and setting generic entry dates around 2040 removes legal uncertainty and secures a lengthy U.S. exclusivity window. This structural clarity preserves multi-year revenue visibility from an existing product and reduces downside risk from near-term generic entry.
Bears Say
Elevated Leverage And Thin EquityHigh leverage with debt roughly four times equity constrains financial flexibility for an unprofitable biopharma. Elevated debt increases refinancing and covenant risk, limits capacity to self-fund late-stage trials or launches, and makes the company more reliant on capital markets or dilutive financing if cash generation falters.
Continued Negative Operating Cash FlowPersistent negative operating cash flow and free cash flow mean the business remains dependent on external financing until sustainable cash generation is achieved. Even with management's runway view, ongoing burn makes the company's funding needs sensitive to SG&A cadence, launch timing, and clinical readouts over the medium term.
High Gross-to-net Discounts & Rising SG&AMaterial gross-to-net deductions (50%+ for AUVELITY/SUNOSI, ~70%+ for SYMBRAVO) and sharply higher SG&A reduce realized revenue and compress margin conversion from sales. These are structural payer and commercialization dynamics that require sustained higher sales volumes and tight expense control to translate headline revenue into durable profitability.
Axsome Therapeutics News
AXSM FAQ
What was Axsome Therapeutics Inc.’s price range in the past 12 months?
Axsome Therapeutics Inc. lowest stock price was $96.09 and its highest was $238.56 in the past 12 months.
What is Axsome Therapeutics Inc.’s market cap?
Axsome Therapeutics Inc.’s market cap is $12.02B.
When is Axsome Therapeutics Inc.’s upcoming earnings report date?
Axsome Therapeutics Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 66 days.
How were Axsome Therapeutics Inc.’s earnings last quarter?
Axsome Therapeutics Inc. released its earnings results on May 04, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$0.844 by -$0.416.
Is Axsome Therapeutics Inc. overvalued?
According to Wall Street analysts Axsome Therapeutics Inc.’s price is currently Undervalued.
Does Axsome Therapeutics Inc. pay dividends?
Axsome Therapeutics Inc. does not currently pay dividends.
What is Axsome Therapeutics Inc.’s EPS estimate?
Axsome Therapeutics Inc.’s EPS estimate is -0.84.
How many shares outstanding does Axsome Therapeutics Inc. have?
Axsome Therapeutics Inc. has 51,459,766 shares outstanding.
What happened to Axsome Therapeutics Inc.’s price movement after its last earnings report?
Axsome Therapeutics Inc. reported an EPS of -$1.26 in its last earnings report, missing expectations of -$0.844. Following the earnings report the stock price went up 8.314%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc.?
Currently, no hedge funds are holding shares in AXSM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Axsome Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$265.13 (40.29% Upside)
$265.13 (40.29% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 92.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
114.05%
12-Months-Change
Fundamentals
Return on Equity
-260.01%
Trailing 12-Months
Asset Growth
19.60%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
AXSM Company Deck
AXSM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong commercial momentum and multiple material positive milestones: 57% YoY revenue growth, AUVELITY's new FDA approval and upgraded $8B peak-sales outlook, sales-force expansions, meaningful payer wins, and an advancing late-stage pipeline with recent BD adding AXS-20. Offsetting risks include materially higher SG&A, elevated gross-to-net discounts (notably for SYMBRAVO), a modest widening of net loss, a slight decline in cash, and remaining clinical/regulatory uncertainties for several pipeline assets. On balance, the positives (robust revenue growth, regulatory wins, and clear commercial execution) significantly outweigh the near-term financial and access headwinds.View all AXSM earnings summariesAXSM Stock 12 Month Forecast
Average Price Target
$265.13
▲(40.29% Upside)
Technical Analysis
Cytokinetics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Nuvalent
―
Ownership Overview
15.34% Insiders
24.40% Mutual Funds
20.88% Other Institutional Investors
25.18% Public Companies and Individual Investors